NRX Pharmaceuticals, Inc. Warrant (NRXPW)

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces FDA Award of Filing Fee Waiver for Upcoming NRX-100 (preservative free ketamine) New Drug Application to Treat Patients with Suicidal Depression

NRx Pharmaceuticals announced that the FDA has granted a filing fee waiver for its upcoming NRX-100 (preservative-free ketamine) New Drug Application to treat suicidal depression. The waiver will enable the company to complete the NDA filing with its current resources.